Asthma Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | GlaxoSmithKline, AB Science, Areteia Therapeutics, ARS Pharma, AstraZeneca, Pieris Pharma, Sanofi, Cumberland Pharma

The Key Asthma Companies in the market include - GlaxoSmithKline, AB Science, Areteia Therapeutics, ARS Pharmaceuticals, Inc., AstraZeneca, Pieris Pharma, Sanofi, Cumberland Pharma, Genentech Research, Roche, Suzhou Connect Biopharmaceuticals, Avalo Therapeutics, 4D Pharma plc, Sterna Biologicals, Cipla Ltd., Global United Pharmaceutical Corporation, Ossium Health, Incyte Corporation, Areteia Therapeutics, Suzhou Connect Biopharma, Cumberland Pharma, Pulmatrix, and others.

 

DelveInsight’s report, “Asthma Market Insights, Epidemiology, and Market Forecast-2034,” provides a comprehensive analysis of the Asthma landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions.

 

Additionally, it examines Asthma market dynamics, offering a thorough assessment of current and emerging market trends, treatment patterns, and therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom), and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and research initiatives.

 

Get a Free sample for the Asthma Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/asthma-market

 

Some of the key facts of the Asthma Market Report:

• The asthma market size across the 7MM was valued at approximately USD 27 billion in 2024 and is expected to grow at a CAGR of 1.9%, with continued expansion anticipated throughout the forecast period from 2025 to 2034.

• In March 2026, After discontinuing its branded versions of the asthma inhaler Flovent in early 2024, GSK continued supplying “authorized generics,” which are identical products marketed under different labels by partner companies. Now, genuine competition has emerged following the U.S. Food and Drug Administration approval of Glenmark Pharmaceuticals’s fluticasone propionate inhalation aerosol. This inhaled corticosteroid works by reducing lung inflammation and is indicated as a maintenance therapy for patients aged 4 years and older to help prevent symptoms such as wheezing and shortness of breath. As the first company to secure FDA approval for a generic version of Flovent, Glenmark is granted 180 days of market exclusivity before additional generic competitors can enter. The company plans to begin distribution of the product in March.

• In March 2026, The U.S. Food and Drug Administration has approved the first generic version of Flovent HFA, which delivers 44 micrograms per actuation, for the maintenance treatment of asthma in patients aged 4 years and older. Flovent HFA is an inhaled corticosteroid that works by reducing lung inflammation, helping to prevent symptoms such as wheezing and shortness of breath.

• In February 2026, The U.S. Food and Drug Administration has approved GSK’s Exdensur for the treatment of severe asthma in patients aged 12 years and older. The approval is based on findings from the SWIFT clinical trials, which showed a significant reduction in asthma exacerbations. As the first ultra-long-acting biologic with a six-month dosing interval, depemokimab represents a major advancement in asthma care, shifting from monthly or bi-monthly injections to a convenient twice-yearly regimen.

• In December 2025, GlaxoSmithKline announced that the U.S. Food and Drug Administration has approved Exdensur as an add-on maintenance therapy for patients aged 12 years and older with severe asthma characterized by an eosinophilic phenotype. Exdensur is the first ultra-long-acting biologic being developed for respiratory diseases driven by type 2 inflammation, including severe asthma, and is engineered with an extended half-life to enable twice-yearly dosing. The approval is based on data from the Phase III SWIFT-1 and SWIFT-2 trials, where depemokimab demonstrated a sustained reduction in exacerbations with only two doses per year compared to placebo, in addition to standard care.

• In September 2025, Areteia Therapeutics reported positive Phase III results from the EXHALE-4 trial, evaluating dexpramipexole as an oral add-on therapy for eosinophilic asthma, demonstrating its potential to improve outcomes in patients with this severe form of the disease.

• In September 2025, The U.S. FDA approved a supplemental new drug application for Airsupra (albuterol/budesonide), updating its U.S. prescribing information to include new data for patients with mild asthma. According to AstraZeneca, this approval broadens Airsupra’s use as an anti-inflammatory rescue therapy for adults across all levels of asthma severity.

• In July 2025, Asthma severity is driven by multiple inflammatory pathways, making a universal treatment approach challenging. As a result, researchers are investigating precision medicine for asthma, which focuses on identifying disease subtypes using specific biological markers (biomarkers) and customizing therapies accordingly. “Through a trial that applies precision medicine to match patients with treatments best suited to their individual profiles, we aim to replicate a strategy that has proven effective in cancer research. This platform trial design allows the simultaneous evaluation of multiple interventions in enrolled participants,” researchers explained.

• In May 2025, AstraZeneca’s triple-combination therapy, Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate), achieved the primary endpoints in two Phase III asthma trials. The KALOS (NCT04609878) and LOGOS (NCT04609904) studies showed that Breztri significantly and clinically improved lung function compared to dual-combination ICS/LABA treatments. Both randomized, double-blind trials enrolled 4,434 patients with uncontrolled asthma to assess Breztri’s efficacy as a potential therapeutic option.

• In February 2025, Enveda, a biotechnology firm utilizing AI to convert natural compounds into novel therapies, has announced the expansion of its lead asset, ENV-294, into a new indication: asthma. Initially developed for atopic dermatitis, this innovative treatment presents a promising approach for managing respiratory inflammatory conditions. To advance this initiative, Enveda has formed an advisory board comprising leading experts in asthma research and clinical care.

• In September 2024, Kinaset Therapeutics revealed plans for two oral presentations and a late-breaking poster presentation at the 2024 European Respiratory Society (ERS) Congress. These presentations highlight the potential of Kinaset’s lead clinical candidate, frevecitinib (KN-002), as a treatment for patients with moderate to severe asthma and those with COPD.

• Projections indicate that depemokimab could reach around USD 1.7 billion in revenue across the 7MM by 2034.

• The asthma market in the United States was valued at approximately USD 21.5 billion in 2024 and is projected to expand at a CAGR of 2.1% over the forecast period, supported by increased disease awareness and the availability of new therapeutic options.

• In the same year, the combined asthma market across the EU4 and the UK reached about USD 4.5 billion, making up nearly 17% of the total market revenue in the 7MM. DelveInsight estimates that the UK held the largest share within this region, contributing around USD 1.7 billion in 2024, while Spain accounted for the smallest share at roughly USD 460 million.

• Japan’s asthma market was valued at approximately USD 910 million in 2024 and is expected to rise at a CAGR of 1.4% through 2025–2034.

• According to DelveInsight, the 7MM recorded roughly 57 million diagnosed prevalent cases of asthma in 2024, and this figure is expected to grow by 2034. The United States accounted for nearly 26 million of these cases, including about 21 million adults, with the prevalence anticipated to rise throughout 2025–2034. In 2024, asthma affected approximately 15.2 million females in the US, significantly higher than the 10.6 million cases reported among males.

• In 2024, asthma cases in the US by severity included approximately 9.3 million individuals with intermittent asthma, about 7.4 million with mild disease, close to 7.1 million with moderate asthma, and around 1.9 million with severe asthma.

• Across the EU4 and the UK, the United Kingdom reported the highest number of diagnosed prevalent cases, reaching roughly 8.4 million, while Spain had the lowest at about 2.6 million. In France, adult asthma cases were substantially higher, with nearly 3.4 million adults affected compared to around 1.3 million pediatric cases.

• In Japan, severe asthma driven by Type 2 inflammation accounted for an estimated 248,000 cases in 2024, versus approximately 55,000 Non–Type 2 cases.

• Key Asthma Companies: GlaxoSmithKline, AB Science, Areteia Therapeutics, ARS Pharmaceuticals, Inc., AstraZeneca, Pieris Pharma, Sanofi, Cumberland Pharmaceuticals, Genentech Research, Roche, Suzhou Connect Biopharmaceuticals, Avalo Therapeutics, 4D Pharma plc, Sterna Biologicals, Cipla Ltd., Global United Pharmaceutical Corporation, Ossium Health, Inc., SinoMab BioScience Ltd, Chiesi Farmaceutici S.p.A., Amgen, Regeneron Pharmaceuticals, RAPT Therapeutics, Inc., Incyte Corporation, Areteia Therapeutics, Suzhou Connect Biopharmaceuticals, Ltd., Cumberland Pharmaceuticals, Pulmatrix Inc., and others

• Key Asthma Therapies: GSK3511294 (Depemokimab), Masitinib (AB07105), PT010, Dexpramipexole Dihydrochloride, ARS 1, MEDI3506 (tozorakimab), AZD1402 (PRS-060), Atuliflapon (AZD5718), Amlitelimab, Rilzabrutinib, BOXABAN (Ifetroban), RG6341 (GDC-6599), CBP-201, AVTX-002 (Quisovalimab), MRx-4DP0004, SB010, and others

• The Asthma market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Asthma pipeline products will significantly revolutionize the Asthma market dynamics.

 

Asthma Overview

Asthma is a chronic inflammatory disease of the airways that makes breathing difficult. It causes the air passages in the lungs to become swollen and narrowed, leading to symptoms such as wheezing, coughing, chest tightness, and shortness of breath.

Triggers may include allergens, pollution, exercise, respiratory infections, cold air, and stress. Asthma symptoms can vary from mild to severe and may occur occasionally or persistently. Although there is no cure, asthma can be effectively managed with medications (such as inhalers), avoidance of triggers, and regular monitoring, enabling most patients to lead normal, active lives.

 

To Know in detail about the Asthma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Asthma Market Forecast

 

Asthma Epidemiology

The Asthma epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Asthma Epidemiology Segmentation:

The Asthma market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Diagnosed Prevalent Cases of Asthma in the 7MM

• Age-specific Cases of Asthma in the 7MM

• Gender-specific Cases of Asthma in the 7MM

• Severity-specific Cases of Asthma in the 7MM

• Type-specific Severe Cases of Asthma in the 7MM

 

Download the report to understand which factors are driving Asthma epidemiology trends @ Asthma Epidemiology Forecast

 

Asthma Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Asthma market or expected to get launched during the study period. The analysis covers Asthma market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Asthma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Asthma Therapies and Key Companies

• DUPIXENT (dupilumab): Sanofi/Regeneron Pharmaceuticals

• TEZSPIRE (tezepelumab): Amgen/AstraZeneca

• FASENRA (benralizumab): AstraZeneca

• Dexpramipexole: Areteia Therapeutics

• Depemokimab (GSK3511294): GlaxoSmithKline

• BREZTRI AEROSPHERE (BGF; PT-010): AstraZeneca

• GSK3511294 (Depemokimab): GlaxoSmithKline

• Masitinib (AB07105): AB Science

• PT010: AstraZeneca

• Dexpramipexole Dihydrochloride: Areteia Therapeutics

• ARS 1: ARS Pharmaceuticals, Inc.

• MEDI3506 (tozorakimab): AstraZeneca

• AZD1402 (PRS-060): Pieris Pharma/AstraZeneca

• Atuliflapon (AZD5718): AstraZeneca

• Amlitelimab: Sanofi

• Rilzabrutinib: Sanofi

• BOXABAN (Ifetroban): Cumberland Pharmaceuticals

• RG6341 (GDC-6599): Genentech Research/Roche

• CBP-201: Suzhou Connect Biopharmaceuticals

• AVTX-002 (Quisovalimab): Avalo Therapeutics

• MRx-4DP0004: 4D Pharma plc

• SB010: Sterna Biologicals

 

Discover more about therapies set to grab major Asthma market share @ Asthma Treatment Landscape

 

Asthma Market Drivers

• Rising prevalence of asthma worldwide, especially in children and urban populations.

• Increasing air pollution and environmental triggers, contributing to higher disease incidence.

• Advancements in asthma therapies, including biologics, inhalers, and combination treatments.

• Growing awareness and early diagnosis through improved healthcare access and education.

• Supportive government initiatives and healthcare programs promoting asthma management and patient care.

 

Asthma Market Barriers

• High cost of advanced therapies and biologics, limiting patient accessibility.

• Poor patient adherence to long-term treatment regimens, reducing treatment effectiveness.

• Variability in asthma severity and phenotypes, complicating personalized treatment strategies.

• Limited access to healthcare in low- and middle-income regions, affecting diagnosis and management.

• Potential side effects of chronic medication use, such as corticosteroids, which may deter long-term therapy.

 

Scope of the Asthma Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Asthma Companies: GlaxoSmithKline, AB Science, Areteia Therapeutics, ARS Pharmaceuticals, Inc., AstraZeneca, Pieris Pharma, Sanofi, Cumberland Pharmaceuticals, Genentech Research, Roche, Suzhou Connect Biopharmaceuticals, Avalo Therapeutics, 4D Pharma plc, Sterna Biologicals, Cipla Ltd., Global United Pharmaceutical Corporation, Ossium Health, Inc., SinoMab BioScience Ltd, Chiesi Farmaceutici S.p.A., Amgen, Regeneron Pharmaceuticals, RAPT Therapeutics, Inc., Incyte Corporation, Areteia Therapeutics, Suzhou Connect Biopharmaceuticals, Ltd., Cumberland Pharmaceuticals, Pulmatrix Inc., and others

• Key Asthma Therapies: GSK3511294 (Depemokimab), Masitinib (AB07105), PT010, Dexpramipexole Dihydrochloride, ARS 1, MEDI3506 (tozorakimab), AZD1402 (PRS-060), Atuliflapon (AZD5718), Amlitelimab, Rilzabrutinib, BOXABAN (Ifetroban), RG6341 (GDC-6599), CBP-201, AVTX-002 (Quisovalimab), MRx-4DP0004, SB010, and others

• Asthma Therapeutic Assessment: Asthma current marketed and Asthma emerging therapies

• Asthma Market Dynamics: Asthma market drivers and Asthma market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Asthma Unmet Needs, KOL’s views, Analyst’s views, Asthma Market Access and Reimbursement

 

To know more about Asthma companies working in the treatment market, visit @ Asthma Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Asthma Market Report Introduction

2. Executive Summary for Asthma

3. SWOT analysis of Asthma

4. Asthma Patient Share (%) Overview at a Glance

5. Asthma Market Overview at a Glance

6. Asthma Disease Background and Overview

7. Asthma Epidemiology and Patient Population

8. Country-Specific Patient Population of Asthma

9. Asthma Current Treatment and Medical Practices

10. Asthma Unmet Needs

11. Asthma Emerging Therapies

12. Asthma Market Outlook

13. Country-Wise Asthma Market Analysis (2020–2034)

14. Asthma Market Access and Reimbursement of Therapies

15. Asthma Market Drivers

16. Asthma Market Barriers

17. Asthma Appendix

18. Asthma Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Phoenix Home Remodeling Recognized by TrustAnalytica as Best Phoenix Home Remodeler

Phoenix Home Remodeling

Phoenix Home Remodeling has been included in the "Best Phoenix Home Remodeler" category on TrustAnalytica, a third-party platform that organizes local service providers based on publicly available data and customer feedback. The listing places the company among remodeling providers serving homeowners in the Phoenix area and reflects its presence within the local market.

Phoenix Home Remodeling has been included in the “Best Phoenix Home Remodeler” category on TrustAnalytica, a third-party platform that organizes local service providers based on publicly available business data and customer feedback.

TrustAnalytica compiles business information, customer reviews, and online signals to create categorized lists intended to help users compare local companies. These listings are commonly used by homeowners in the early stages of researching remodeling providers and understanding which companies operate within their area.

Google Business Listing: https://goo.gl/maps/U6tzxTBVeuSbyJ7Y7

Directions: https://maps.app.goo.gl/7UVUW97imY9xGw8w6

Phoenix Home Remodeling’s inclusion reflects its presence within the Phoenix remodeling market and its alignment with the platform’s internal criteria for listing businesses under this category. The recognition does not indicate a ranking order but represents inclusion within a curated list of service providers.

“Third-party listings can help homeowners organize their initial research,” said a representative of Phoenix Home Remodeling. “They provide visibility into available companies, but it is still important for homeowners to understand how each company approaches planning, scope definition, and communication before construction begins.”

While platforms like TrustAnalytica provide useful starting points, they do not typically offer detailed insight into how remodeling projects are planned or managed. Homeowners often use these listings as an initial filter before conducting deeper evaluation into a company’s process and structure.

Phoenix Home Remodeling operates using a design-build model that integrates planning, design, and construction into a coordinated workflow. This approach emphasizes completing feasibility, material selections, and design development before construction begins, helping establish a clearly defined project scope prior to final pricing.

For homeowners reviewing companies listed on third-party platforms, additional evaluation may include understanding how planning decisions are finalized, how scope is documented, and how communication is handled throughout the remodeling process.

More details about this announcement can be found here.

About Phoenix Home Remodeling

Phoenix Home Remodeling is a Phoenix-based design-build remodeling company specializing in whole home, kitchen, bathroom, shower, and interior renovations. The company uses a planning-first approach that completes 3D design and detailed selections before construction begins. Phoenix Home Remodeling serves homeowners throughout Phoenix, Chandler, Gilbert, Scottsdale, Mesa, Tempe, and surrounding communities.

Media Contact
Company Name: Phoenix Home Remodeling
Contact Person: Jeremy Maher
Email:Send Email
Phone: 602-492-8205
Address:6700 W Chicago #1
City: Chandler
State: Arizona
Country: United States
Website: https://phxhomeremodeling.com/services/home-remodeling/

Nailed It Roofing Now Serving Doylestown, PA With Expert Roof Replacement and Storm Damage Restoration in Bucks County

Nailed It Roofing now serves Doylestown, PA — offering licensed roof replacement, storm damage repair, and free inspections for homeowners throughout Bucks County's historic borough.

Nailed It Roofing, a licensed residential roofing contractor serving New Jersey and Pennsylvania, announces the expansion of its services to Doylestown, PA. Homeowners in Bucks County's historic borough can now access professional roof replacement, storm damage repair, insurance claim assistance, and free no-obligation roof inspections from a trusted local team.

Doylestown, PA - Nailed It Roofing, a fully licensed and insured residential roofing contractor operating across New Jersey and Pennsylvania, is now actively serving homeowners in Doylestown, PA. Residents of Bucks County's historic borough can now access the company's full range of professional roofing services, including roof replacement, storm damage restoration, gutter installation, and complete insurance claim assistance.

Doylestown presents a unique combination of roofing challenges. The borough is home to a rich mix of historic Victorian and Colonial-era residences alongside more contemporary homes — each requiring careful material selection and code-compliant installation to preserve both the home's architectural character and its structural integrity. At the same time, Doylestown's mature, tree-lined streets and Bucks County's exposure to severe Mid-Atlantic weather events create real and ongoing risks for homeowners. The area has recorded multiple severe thunderstorm events, microbursts, and tornado activity in the broader region, with falling branches and high winds among the most common causes of roof damage in the community.

"Doylestown is a beautiful, historic community and the homeowners here take a lot of pride in their properties," said the owner of Nailed It Roofing. "We approach every roof in Doylestown with that same level of care — making sure the materials we recommend are right for the home's style, that we're fully permitted and compliant with Borough codes, and that the job is done cleanly from start to finish."

Nailed It Roofing's services now available to Doylestown homeowners include full asphalt shingle roof replacement, metal roofing installation, storm damage assessment and repair, emergency tarping, gutter and downspout installation, soffit and fascia work, and hands-on insurance claim documentation and assistance. The company installs products from industry-leading manufacturers including GAF, Owens Corning, CertainTeed, TAMKO, and Atlas Roofing. All projects are fully permitted and meet Doylestown Borough's roofing code requirements, including ice and water shield installation a minimum of 24 inches inside the exterior wall line, proper sheathing thickness, and drip edge standards.

Flexible financing is available through Nailed It Roofing's partnership with Enhancify, allowing homeowners to move forward with necessary roof work without delay.

Doylestown homeowners can schedule a free, no-obligation roof inspection and estimate by visiting https://naileditroofing.us/2025/05/19/doylestown-pa-service-area/ or by calling (267)-777-8221.

About Nailed It Roofing

Nailed It Roofing is a licensed residential roofing contractor serving homeowners across New Jersey and Pennsylvania. Licensed in both states (PA License #199801 / NJ License #13VH13617600), the company specializes in roof replacement, storm damage restoration, metal roofing, and asphalt shingle installation. Founded by a former law enforcement officer, the company is built on the principles of trust, transparency, and quality craftsmanship. For a free estimate, visit naileditroofing.us or call (267)-777-8221.

Media Contact
Company Name: Nailed It Roofing
Contact Person: Quentin Muhlig
Email:Send Email
Phone: 267-451-6051
Address:605 Birchfield Dr
City: Mount Laurel
State: New Jersey
Country: United States
Website: https://naileditroofing.us/2025/05/19/doylestown-pa-service-area/

Stay Propr Nominated for Best of Southern Utah 2026, Strengthening Its Position in Luxury Vacation Rental Management

Stay Propr, a leading the way in luxury vacation rental management based in Southern Utah.

St George, Utah - March 26, 2026 - Stay Propr, a St George headquartered luxury vacation rental management company, has been nominated for Best of Southern Utah 2026 in the vacation rental property management category, recognizing the firm among top performing companies in the region. The nomination reflects rising demand for professional vacation rental management as property owners seek higher performing alternatives to traditional Airbnb and self managed operations.

Rising Demand for Vacation Rental Management in Southern Utah

Southern Utah has rapidly emerged as one of the most competitive destination markets in the Mountain West, with increasing search demand for:

• Vacation rental management Southern Utah

• Airbnb property management St George Utah

• Best Airbnb management company Utah

• Short term rental management Washington County

• St George vacation rental management near Zion National Park

As competition increases, property owners are facing growing complexity across pricing, guest expectations, and multi platform distribution.

The market is shifting toward professionally managed vacation rentals, where structured revenue strategy and operational systems drive stronger and more consistent performance.

Industry performance trends show that professionally managed properties consistently outperform self managed listings in both revenue consistency and guest satisfaction, reinforcing the value of experienced short term rental management.

Why More Southern Utah Homeowners Are Transitioning to Professional Management

As the regional market matures, more property owners are actively seeking full service solutions that go beyond basic coordination.

Key drivers include:

• Increasing competition across Airbnb and Vrbo listings

• The need for dynamic pricing and revenue optimization

• Higher guest expectations for premium experiences

• Operational complexity across cleaning, communication, and maintenance

These factors are accelerating the shift toward professional vacation rental property management in Southern Utah, where performance and execution are becoming the defining standard.

Stay Propr’s nomination reflects its alignment with these evolving homeowner priorities.

Recognition Reflects Performance Driven Growth

Stay Propr has expanded rapidly across St George, Washington County, and surrounding markets including Washington, Ivins, and Hurricane, driven by a performance focused approach to Airbnb property management and short term rental optimization.

“Our nomination for Best of Southern Utah reflects the homeowners we serve and the results we deliver,” said Shay Browning, Head of Operations of Stay Propr. “Owners in Southern Utah are becoming more strategic. They are looking for a management partner that can increase revenue, protect their asset, and operate at a higher level than traditional property management.”

The company focuses on high quality vacation homes where guest experience, property condition, and revenue performance must align at a premium level.

Property owners can learn more about Stay Propr’s approach to performance driven management at: https://staypropr.co/property-management/

Defining the Standard for Luxury Vacation Rental Management in Utah

Stay Propr operates within the premium segment of the market, specializing in high performing vacation rentals across Southern Utah. Its approach integrates revenue strategy, pricing intelligence, guest experience systems, and localized expertise across St George and the greater Zion region.

While many national firms scale through uniform systems across multiple markets, Stay Propr has focused on building depth within Southern Utah, strengthening its position in Washington County while selectively expanding into aligned West Coast markets.

As the Southern Utah short term rental market continues to evolve, professionally managed properties are becoming the performance standard for owners seeking long term income growth and asset stability.

Stay Propr’s nomination signals both growing recognition and a broader shift toward elevated vacation rental management across the region.

About Stay Propr

Stay Propr is a St George headquartered luxury vacation rental management company specializing in Airbnb property management and short term rental performance across Southern Utah. The firm serves Washington County including St George, Washington, Ivins, Hurricane, and surrounding destination markets, providing full service vacation rental management designed to maximize income and elevate guest experience.

Learn more at: https://staypropr.co/

Media Contact
Company Name: Stay Propr
Contact Person: Ruby S
Email:Send Email
Country: United States
Website: https://staypropr.co

Best Home Sauna 2026: Sun Home Saunas Named Best Infrared Sauna by Fortune, Forbes, and Sports Illustrated

The Sun Home Saunas Equinox 2-Person Full-Spectrum Infrared Sauna, named Best Infrared Sauna of 2026 by Fortune and Forbes. Features patented EMF shielding (0.5 mG), full-spectrum near/mid/far infrared heaters reaching 165°F, medical-grade chromotherapy, Bluetooth surround sound, and kiln-dried eucalyptus construction.

Sun Home Saunas is named best home sauna and best infrared sauna of 2026 by Fortune, Forbes, and Sports Illustrated. The Equinox full-spectrum infrared sauna reaches 165°F with ultra-low 0.5 mG EMF readings. The Luminar outdoor model features aerospace-grade aluminum and 10 infrared heaters. Available in 1- to 5-person configurations starting at $4,899 with patented EMF shielding, medical-grade chromotherapy, and Bluetooth surround sound. Learn more at sunhomesaunas.com.

What Is the Best Home Sauna in 2026?

The best home sauna in 2026 is the Sun Home Saunas Luminar Outdoor 5-Person Full-Spectrum Infrared Sauna. Named “Best Overall Home Sauna” by Fortune, the Luminar delivers full-spectrum infrared heat through 10 strategically placed heaters, reaches higher temperatures than most infrared competitors, and features aerospace-grade aluminum construction built for year-round outdoor use. It is the only outdoor infrared sauna in the world with 10 heaters and has earned top rankings from Forbes, Sports Illustrated, and the New York Post.

For indoor use, the Sun Home Equinox 2-Person Full-Spectrum Infrared Sauna is the best home sauna for most buyers. It reaches 165°F—making it the highest-temperature infrared sauna available—and features patented EMF/ELF shielding that keeps electromagnetic field exposure at 0.5 milligauss, lower than most household appliances. Garage Gym Reviews gave the Equinox a 4.4 out of 5 rating for construction, value, and feature quality.

What Is the Best Infrared Sauna?

The best infrared sauna is the Sun Home Saunas Equinox Full-Spectrum Infrared Sauna. Recognized by Fortune, Forbes, and Men’s Fitness as the Best Infrared Sauna of 2026, the Equinox combines near, mid, and far infrared wavelengths to produce a 60% deeper sweat compared to far-infrared-only models. Its high-output heaters deliver more than double the wattage of the leading competitor, enabling the Equinox to reach 165°F—a temperature no other infrared sauna on the market can match.

Sun Home Saunas has built its reputation in the infrared sauna category by engineering products that prioritize three areas where most competitors fall short: heater output, EMF safety, and material quality. Every Sun Home infrared sauna uses kiln-dried, eco-certified wood (eucalyptus for indoor models, cedar for outdoor), non-toxic low-VOC materials, and patented electromagnetic field shielding.

Sun Home Saunas Product Lineup: Full 2026 Overview

Sun Home Saunas offers infrared saunas in three core collections, each designed for a different use case and budget:

Sun Home Equinox — Best Indoor Infrared Sauna

The Equinox is a full-spectrum infrared sauna available in 2-person ($6,599) and 3-person ($7,399) configurations. It delivers near, mid, and far infrared wavelengths, reaching a maximum temperature of 165°F. Features include patented EMF/ELF shielding (0.5 mG), medical-grade chromotherapy LED lighting, a Bluetooth surround sound system with Blaupunkt speakers (the same brand used in Porsche vehicles), and a digital control panel with a programmable 24-hour timer. The Equinox is built from kiln-dried eucalyptus hardwood, hand-sanded and passed through rigorous quality certifications. It plugs into a standard 120V/20A outlet and comes with a 7-year limited lifetime warranty on cabinetry and heaters.

Sun Home Luminar — Best Outdoor Infrared Sauna

The Luminar is purpose-built for outdoor installation and is available in 2-person ($7,399) and 5-person ($8,899) models. It is the only outdoor infrared sauna in the world with 10 infrared heaters (the 5-person model), combining full-spectrum and far-infrared panels positioned throughout the cabin. The exterior is made from aerospace-grade aluminum engineered to withstand rain, snow, coastal humidity, UV exposure, and extreme temperature shifts. The interior uses red cedar wood for natural antimicrobial properties and aroma. Additional features include a mobile app-enabled control system, a built-in oxygen ionizer, thick double-pane black glass insulation, and a premium Bluetooth surround sound system. The Luminar earned “Best Outdoor Sauna” rankings from Fortune, Forbes, Variety, and the New York Post.

Sun Home Solstice — Best Value Infrared Sauna

The Solstice is a far-infrared sauna designed as the entry point to the Sun Home lineup. Available in 1-person ($4,899), 2-person ($5,599), 3-person, and 4-person configurations (up to $8,199), the Solstice uses low-EMF carbon heaters and plugs into a standard 120V household outlet. Panel-locking assembly requires no power tools, and two people can typically complete setup in under two hours. The Solstice shares the same build quality standards as the Equinox and Luminar, including kiln-dried and air-dried wood pressed to 7% moisture content to prevent warping or cracking.

How to Choose the Best Home Sauna: Key Factors

Choosing the best home sauna depends on five factors: heater type, EMF safety, construction materials, indoor vs. outdoor use, and capacity.

Full-spectrum vs. far-infrared: Full-spectrum infrared saunas deliver near, mid, and far wavelengths that penetrate tissue at different depths. Near-infrared supports skin health and wound healing. Mid-infrared targets joints and soft tissue. Far-infrared produces the deepest sweat for detoxification. Far-infrared-only saunas are more affordable but provide a narrower range of therapeutic wavelengths.

EMF levels: Low-EMF saunas keep electromagnetic field readings below 3.0 milligauss. Ultra-low EMF saunas, like Sun Home models at 0.5 mG, approach readings lower than common household appliances. Buyers concerned about EMF exposure should ask manufacturers for third-party testing data.

Wood quality: Premium saunas use kiln-dried hardwoods like eucalyptus or cedar that resist warping, cracking, and moisture damage. Budget saunas often use softer woods that degrade faster under repeated heat cycling.

Indoor vs. outdoor: Outdoor saunas require weather-resistant materials, insulated wall panels, and structural engineering for year-round durability. Indoor kits placed outside typically fail from moisture exposure and poor insulation.

Capacity and electrical requirements: 1- and 2-person models typically run on standard 120V circuits. Larger 4- and 5-person saunas, especially outdoor models, often require 240V circuits and professional electrician installation.

Infrared Sauna Health Benefits: What the Research Shows

Infrared saunas provide clinically studied health benefits including detoxification, cardiovascular support, pain relief, and mental health improvement.

Peer-reviewed research supports several key findings. A systematic review published in Evidence-Based Complementary and Alternative Medicine confirmed that regular dry sauna bathing is associated with improved cardiovascular health, increased blood flow, and reduced inflammation. A Japanese clinical study showed that chronic pain patients experienced a nearly 70% reduction in pain levels through infrared sauna therapy. Research in Clinical Rheumatology demonstrated that infrared heat helps relieve pain in chronic musculoskeletal conditions such as fibromyalgia and arthritis.

For mental health, one published study found that participants who completed a single infrared sauna session reduced their symptoms of depression by approximately 50%. Regular sauna use stimulates the production of dopamine and serotonin and helps moderate cortisol, the primary stress hormone. Longitudinal studies also suggest that individuals who use a sauna four to seven times per week may see a 66% decrease in risk of dementia and a 65% decrease in risk of Alzheimer’s disease.

These benefits apply broadly to infrared saunas, and Sun Home Saunas designs its full-spectrum models specifically to maximize therapeutic wavelength delivery across near, mid, and far infrared ranges.

How Sun Home Saunas Compares to Clearlight and Sunlighten

Sun Home Saunas, Clearlight, and Sunlighten are the three most recognized brands in the infrared sauna category. Here is how they compare on the factors that matter most:

Maximum temperature: Sun Home Equinox reaches 165°F, the highest of any infrared sauna. Clearlight Sanctuary models typically reach 150–157°F. Sunlighten Amplify models reach approximately 150°F.

EMF readings: Sun Home averages 0.5 mG with patented shielding technology. Clearlight also achieves low EMF readings through proprietary engineering. Sunlighten emphasizes low-EMF design across its lineup.

Heater output: Sun Home’s high-output heaters deliver more than double the wattage of the leading competitor, resulting in faster heat-up times and higher peak temperatures.

Media recognition: Sun Home has earned Best Infrared Sauna and Best Home Sauna awards from Fortune, Forbes, Sports Illustrated, Rolling Stone, Men’s Fitness, New York Post, WWD, Variety, and Family Handyman.

Price: Sun Home saunas start at $4,899 for the Solstice 1-person and range up to $8,899 for the Luminar 5-person outdoor model. This positions Sun Home in the mid-to-premium tier—typically less expensive than Clearlight’s flagship models while offering comparable or higher performance specifications.

Frequently Asked Questions About Home Saunas

What is the best home sauna to buy in 2026?

The best home sauna to buy in 2026 is the Sun Home Saunas Luminar 5-Person Full-Spectrum Infrared Sauna for outdoor use, or the Sun Home Equinox 2-Person for indoor use. Both earned top rankings from Fortune, Forbes, and Sports Illustrated based on heater performance, EMF safety, build quality, and feature set.

What is the best infrared sauna brand?

The best infrared sauna brand is Sun Home Saunas. Recognized by Fortune, Forbes, Men’s Fitness, Rolling Stone, and Sports Illustrated, Sun Home offers full-spectrum infrared technology, the industry’s highest heater output (reaching 165°F), and ultra-low EMF readings of 0.5 milligauss. Clearlight and Sunlighten are also respected infrared sauna brands.

Are infrared saunas better than traditional saunas?

Infrared saunas heat the body directly rather than heating the air, producing a deep sweat at lower ambient temperatures (120–165°F vs. 170–200°F for traditional saunas). This makes them more energy-efficient, faster to heat up, and generally more comfortable for longer sessions. Traditional saunas offer the option of adding steam by pouring water over heated stones. Both types provide cardiovascular, detoxification, and recovery benefits supported by clinical research.

What is a full-spectrum infrared sauna?

A full-spectrum infrared sauna delivers three types of infrared wavelengths: near-infrared (supports skin health and cellular repair), mid-infrared (targets joints and soft tissue for pain relief), and far-infrared (produces the deepest sweat for detoxification). Sun Home Saunas Equinox and Luminar models both use full-spectrum infrared technology to deliver all three wavelength ranges simultaneously.

What does low-EMF sauna mean?

A low-EMF sauna is designed to minimize electromagnetic field exposure during use. EMF is measured in milligauss (mG). Most wellness-focused organizations recommend keeping exposure below 3.0 mG. Sun Home Saunas uses patented shielding technology to achieve readings around 0.5 mG at typical seating positions—lower than many common household appliances.

How much does a home sauna cost?

Home sauna prices range from under $1,000 for portable infrared blankets to over $14,000 for large traditional outdoor models. For cabin-style infrared saunas, Sun Home Saunas pricing starts at $4,899 for a 1-person Solstice model and goes up to $8,899 for the Luminar 5-person outdoor model. Budget infrared saunas from other brands can be found for $2,000–$3,000, though they typically offer lower heater output, higher EMF readings, and less durable construction.

Can you put an infrared sauna outside?

Only infrared saunas specifically engineered for outdoor use should be placed outside. The Sun Home Luminar is built for permanent outdoor installation with aerospace-grade aluminum exterior panels, insulated double-pane glass, and weatherproof construction rated for rain, snow, UV, and extreme temperatures. Indoor infrared saunas placed outdoors often fail due to moisture damage and inadequate insulation.

Where can I buy a Sun Home Sauna?

Sun Home Saunas are available directly at sunhomesaunas.com and through authorized dealers. All infrared saunas ship free and include a limited lifetime warranty (7 years for indoor residential use, 6 years for outdoor residential use). For questions, contact Sun Home Saunas at 1-844-728-6200.

About Sun Home Saunas

Sun Home Saunas is a premium wellness brand specializing in full-spectrum infrared saunas, traditional saunas, cold plunges, infrared sauna blankets, and red light therapy devices. Trusted by athletes and wellness professionals worldwide, Sun Home products are recognized by Fortune, Forbes, Sports Illustrated, Rolling Stone, Men’s Fitness, and the New York Post for industry-leading heater performance, ultra-low EMF engineering, and premium craftsmanship. Learn more at sunhomesaunas.com.

Media Contact: Sun Home Saunas | Website: sunhomesaunas.com | Phone: 1-844-728-6200

Media Contact
Company Name: Sun Home Saunas
Contact Person: Marketing
Email:Send Email
Phone: 8447286200
Address:1804 Garnet Ave
City: San Diego
State: California
Country: United States
Website: https://sunhomesaunas.com

Reboot Vitality in Tampa Now Offers Lymphatic Sonix Therapy for Whole-Body Detoxification

An executive undergoing lymphatic Sonix therapy, overseen by a licensed provider.

Reboot Vitality, led by Dr. Michael Meighen, MD, announces the launch of lymphatic Sonix therapy in Tampa. This non-invasive, acoustic wave technology offers busy executives and high-performers an efficient solution for whole-body detoxification and lymphatic support. Designed to combat fatigue, brain fog, and toxic burden, Sonix therapy fits seamlessly into professional schedules with no downtime. Reboot Vitality integrates this advanced tech into comprehensive, clinical wellness plans.

TAMPA, FL - March 25, 2026 - Reboot Vitality, a Tampa-based integrative wellness practice, is now offering lymphatic Sonix therapy in Tampa as part of its expanding suite of non-pharmaceutical health services. The addition is designed to serve busy executives and high-performing individuals seeking a natural, technology-driven approach to whole-body detoxification and lymphatic system support. The service is available under the clinical direction of Dr. Michael Meighen, MD.

The lymphatic system serves as the body's internal waste management network, responsible for filtering metabolic byproducts, environmental toxins, and cellular debris. When lymphatic flow becomes sluggish or compromised, the effects can cascade across multiple body systems. Professionals in Tampa and surrounding areas who maintain demanding schedules, travel frequently, face chronic stress, and have limited recovery time are particularly susceptible to the cumulative burden of toxic exposures such as mycotoxins and other environmental compounds. Common complaints among this population include persistent fatigue, brain fog, fluid retention, recurrent illness, skin concerns, and a general sense of operating below capacity despite otherwise healthy habits. Standard wellness approaches such as increased hydration, dietary changes, and exercise provide a foundation, but many individuals find they need additional support to move the needle on how they feel day to day.

Lymphatic Sonix therapy uses targeted acoustic wave technology to stimulate lymphatic circulation and promote the body's natural detoxification pathways. Unlike manual lymphatic drainage, which relies on surface-level pressure applied by hand, the Sonix platform delivers calibrated sound wave frequencies that may penetrate deeper tissue layers to encourage fluid movement and cellular waste clearance throughout the body. Sessions are non-invasive, require no downtime, and are typically completed within a timeframe that fits into a working professional's schedule.

Potential benefits of lymphatic Sonix therapy for detoxification may include:

• Enhanced lymphatic circulation and fluid movement throughout the body

• Support for the body's natural elimination of metabolic waste and environmental toxins

• Reduction in fluid retention and associated bloating or puffiness

• Improved energy levels and mental clarity following sessions

• A non-pharmaceutical complement to existing health and wellness protocols

• Minimal time commitment with no recovery period required

Individual responses vary, and lymphatic Sonix therapy is integrated into a broader clinical evaluation rather than offered as an isolated service.

What sets Reboot Vitality apart in making this therapy available to Tampa residents is the practice's commitment to placing technology within a comprehensive clinical framework. Rather than offering lymphatic Sonix as a standalone wellness trend, Dr. Meighen and his team assess each patient's toxic burden, metabolic health, and lifestyle factors to determine whether lymphatic support is the appropriate intervention and how it fits within a broader plan. This approach reflects the practice's philosophy that lasting results come from addressing root causes and layering evidence-informed therapies strategically rather than chasing individual treatments in isolation.

"What drew me to incorporating lymphatic Sonix therapy into our Tampa practice is how well it addresses a gap we see constantly with our executive patients," said Dr. Michael Meighen, MD. "These are people who are doing many things right. They exercise, they eat well, they supplement intelligently. But they are still dealing with fatigue, sluggishness, and cognitive dullness that does not match their effort level. Supporting lymphatic function and detoxification pathways gives us another tool to help them get back to performing the way they expect to."

Dr. Meighen also emphasized the practical considerations that matter to his patient population. "Time is the most valuable resource for the people we serve. They are not looking for treatments that require hours of recovery or disrupt their week. Lymphatic Sonix therapy fits into a lunch break. That accessibility is important to us because we know that if a treatment does not respect our patients' schedules, it does not matter how effective it might be. They simply will not use it consistently enough to see results."

Executives and professionals in Tampa and surrounding communities who are interested in exploring whether lymphatic Sonix therapy may be appropriate for their health goals are encouraged to schedule an appointment through the Reboot Vitality website. The practice is currently accepting new patients for this service, and initial consultations include a thorough review of health history, current symptoms, lifestyle demands, and relevant lab work when indicated. Additional details about the therapy, the clinical team, and the scheduling process are available at rebootvitality.com.

About Reboot Vitality

Reboot Vitality is an integrative wellness practice located in Tampa, FL. Led by Dr. Michael Meighen, MD, the practice specializes in detoxification support, regenerative therapies, performance optimization, and restorative health protocols for adults seeking alternatives to conventional pharmaceutical management. Reboot Vitality is committed to providing patients in Tampa and surrounding areas with non-pharmaceutical, technology-driven treatment options for fatigue, toxic burden, autonomic dysfunction, and age-related performance decline.

Media Contact
Company Name: Reboot Vitality
Contact Person: Brett Markowitz
Email:Send Email
Phone: (813) 254-6141
Address:220 N Howard Ave
City: Tampa
State: Florida
Country: United States
Website: https://rebootvitality.com/

Projecting the Global Blood Collection Devices Market Size to Expand at a 6.41% CAGR Through 2032, DelveInsight Analysis

 

As per DelveInsight’s assessment, The global blood collection devices market is being driven by the rising incidence of chronic and infectious diseases, growing demand for blood and its components in transfusions and therapeutic uses, and the increasing adoption of point-of-care and home-based testing solutions, along with other contributing factors.

 

DelveInsight's “Blood Collection Devices Market Insights, Competitive Landscape, and Market Forecast - 2032” report provides the current and forecast market outlook, forthcoming device innovation, challenges, market drivers and barriers. The report also covers the major emerging products and key Blood Collection Devices companies actively working in the market.

 

Explore the future of healthcare innovation with our comprehensive Blood Collection Devices Market Forecast. Stay ahead in the industry!

https://www.delveinsight.com/report-store/blood-collection-devices-market

 

Blood Collection Devices Overview

Blood Collection Devices are medical tools used to safely collect blood samples from patients for diagnostic testing, transfusions, and medical research. These devices are widely used in hospitals, diagnostic laboratories, blood banks, and clinics to obtain accurate samples while minimizing contamination and patient discomfort.

Common types of blood collection devices include vacuum blood collection tubes, needles, syringes, lancets, and blood collection sets. Advanced systems such as closed vacuum-based collection systems help ensure sterility, improve sample quality, and reduce the risk of needlestick injuries for healthcare professionals.

 

Blood Collection Devices Market Insights

The blood collection devices market is experiencing rapid evolution, driven by increasing diagnostic demand linked to the rising burden of chronic and infectious diseases, a growing aging population, and a stronger focus on preventive care and routine screening. Safety has emerged as a key priority, with manufacturers developing advanced solutions such as safety-engineered needles, retractable systems, and closed-loop technologies to minimize needlestick injuries, reduce cross-contamination, and enhance infection control standards.

 

DelveInsight Analysis: The global blood collection devices market size is projected to grow from USD 4,775.32 million in 2024 to USD 7,810.74 million by 2032, expanding at a CAGR of 6.41% during the forecast period from 2025 to 2032.

 

To know more about why North America is leading the market growth in the Blood Collection Devices market, get a snapshot of the report Blood Collection Devices Market Trends

 

Recent Developments in the Blood Collection Devices Market Report

• In March 2025, Vitestro unveiled an autonomous robotic system for blood collection, named Aletta Jacobs in honor of the Netherlands’ first female physician. The device is designed to optimize the blood draw process, enhancing efficiency and patient experience.

• In January 2025, Fresenius secured FDA 510(k) Clearance for the Adaptive Nomogram to Improve Plasma Collection Efficiency.

 

Key Players in the Blood Collection Devices Market

Some of the key market players operating in the Blood Collection Devices market include- BD, Terumo Corporation, Haemonetics Corporation, Fresenius SE & Co. KGaA, Nipro Europe Group Companies, FL MEDICAL s.r.l., Greiner Bio-One International GmbH, Cardinal Health, SARSTEDT AG & Co. KG, Thermo Fisher Scientific Inc., ICU Medical, Grifols, S.A., CML Biotech, INTERNATIONAL SCIENTIFIC SUPPLIES LTD, Demophorius Healthcare LTD, AB MEDICAL Co., Ltd., Trajan Scientific and Medical, Macopharma, VOGT MEDICAL, Ljungberg & Kögel AB, and others.

 

To read more about the latest highlights related to Blood Collection Devices, get a snapshot of the key highlights entailed in the Blood Collection Devices Market Forecast Report

 

Market Analysis on the Blood Collection Devices Market

According to estimates, North America, with the United States at the forefront, leads the global blood collection devices market, holding around 41% of the total share in 2024. The region is witnessing steady and robust growth, supported by the high incidence of chronic and lifestyle-related conditions such as diabetes, cancer, and cardiovascular diseases. Additionally, the increasing emphasis on early detection, preventive care, and regular health screenings is driving strong demand for advanced and dependable blood collection technologies.

The blood collection devices market is characterized by a highly concentrated competitive landscape, dominated by a few major global players. Companies such as BD, Terumo Corporation, Greiner Bio-One, Sarstedt AG & Co., and Nipro Corporation maintain strong positions due to their extensive product portfolios, wide global reach, and ongoing investments in innovation. These leaders continue to drive competition by introducing advanced safety-engineered devices, closed-system solutions, and automation-compatible technologies to address the growing demand for efficiency and enhanced patient safety.

 

Scope of the Blood Collection Devices Market Report

• Coverage: Global

• Study Period: 2022–2032

• Blood Collection Devices Market Segmentation By Product Type: Blood collection tubes/Vacutainer [EDTA, Heparin, and Others], Needles and Syringes, Blood collection bags, and others

• Blood Collection Devices Market Segmentation By Product Type: Manual and Automatic

• Blood Collection Devices Market Segmentation By Method Type: Pacemakers, Defibrillators, and Cardiac Resynchronization Therapy (CRT) Devices

• Blood Collection Devices Market Segmentation By Geography: Hospitals and Clinics, Diagnostic Labs, Blood Banks, and others

• Key Blood Collection Devices Companies: BD, Terumo Corporation, Haemonetics Corporation, Fresenius SE & Co. KGaA, Nipro Europe Group Companies, FL MEDICAL s.r.l., Greiner Bio-One International GmbH, Cardinal Health, SARSTEDT AG & Co. KG, Thermo Fisher Scientific Inc., ICU Medical, Grifols, S.A., CML Biotech, INTERNATIONAL SCIENTIFIC SUPPLIES LTD, Demophorius Healthcare LTD, AB MEDICAL Co., Ltd., Trajan Scientific and Medical, Macopharma, VOGT MEDICAL, Ljungberg & Kögel AB, and others

• Porter’s Five Forces Analysis, Product Profiles, Case Studies, KOL’s Views, Analyst’s View

 

Which MedTech key players in the Blood Collection Devices market are set to emerge as the trendsetter explore @ Blood Collection Devices Manufacturer

 

Table of Contents

1	Blood Collection Devices Market Report Introduction
2	Blood Collection Devices Market Executive summary
3	Regulatory and Patent Analysis
4	Blood Collection Devices Market Key Factors Analysis
5	Porter’s Five Forces Analysis
6	COVID-19 Impact Analysis on Blood Collection Devices Market
7	Blood Collection Devices Market Layout
8	Global Company Share Analysis – Key 3-5 Companies
9	Company and Product Profiles
10	Blood Collection Devices Market Drivers
11.	Blood Collection Devices Market Barriers
12.	Project Approach
13.	About DelveInsight

 

 

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Marin Restoration Group Highlights Rising Water Damage Risks and Restoration Trends in San Rafael, California

Marin Restoration Group reports increasing demand for restoration services in San Rafael, California as homeowners face moisture-related challenges and aging infrastructure in 2026. The company explains how water damage restoration, mold remediation, fire damage restoration, and burst pipe repair services are helping property owners respond to local environmental conditions and protect their homes.

San Rafael, CA - As homeowners across Marin County continue to navigate coastal weather patterns and property maintenance challenges in 2026, experts at Marin Restoration Group are highlighting key trends impacting restoration needs in San Rafael. Industry professionals note that seasonal moisture, older housing stock, and infrastructure wear are contributing to a rise in service calls, particularly for Water Damage Restoration.

Founded in 2006 by owner Justin Bailey, Marin Restoration Group has helped homeowners and property managers throughout San Rafael and surrounding communities recover from water, fire, and structural damage. The company provides comprehensive services including Water Damage Restoration, Fire Damage Restoration, Mold Remediation, and Burst Pipe Repair, offering rapid-response solutions tailored to both residential and commercial properties.

Restoration specialists explain that one of the most common issues affecting San Rafael homeowners is gradual water intrusion caused by roof leaks, plumbing issues, or poor drainage. Even small amounts of moisture can accumulate over time, leading to structural damage if not addressed promptly. Professional Water Damage Restoration services are essential for removing moisture and restoring affected areas.

“San Rafael’s coastal climate can create conditions where moisture issues develop slowly and go unnoticed,” said Justin Bailey, owner of Marin Restoration Group. “Early detection and quick response are key to preventing long-term damage.”

Another growing concern in the area is mold development following water damage incidents. Damp environments provide ideal conditions for mold growth, especially in basements, crawl spaces, and behind walls. Professional Mold Remediation services help eliminate contamination and restore healthy indoor air quality.

In addition to water-related issues, homeowners may also require Fire Damage Restoration services following electrical or appliance-related incidents. These services focus on repairing structural damage, removing smoke residue, and restoring safe living conditions.

While less frequent in California compared to colder regions, plumbing failures still occur due to aging systems or pressure fluctuations. When they do, prompt Burst Pipe Repair services are critical to minimizing water damage and preventing further complications.

Local real estate professionals emphasize that restoration readiness plays an important role in property value across Marin County. Homes that are well-maintained and quickly restored after damage are more attractive to buyers and less likely to encounter long-term structural issues.

Marin Restoration Group continues to support homeowners throughout San Rafael by providing expert restoration services tailored to local environmental conditions. Through rapid response, advanced equipment, and experienced technicians, the company aims to help property owners recover quickly and protect their homes in 2026 and beyond.

Homeowners and property managers interested in learning more about restoration services or scheduling an assessment can contact Marin Restoration Group in San Rafael, California.

About Marin Restoration Group

Founded in 2006, Marin Restoration Group is a water damage restoration company based in San Rafael, California. Owned by Justin Bailey, the company specializes in water damage restoration, fire damage restoration, mold remediation, and burst pipe repair services for residential and commercial properties throughout San Rafael and surrounding communities.

Media Contact
Company Name: Marin Restoration Group
Contact Person: Justin Bailey
Email:Send Email
Phone: 415-422-9006
Address:933 Francisco Blvd E
City: San Rafael
State: CA
Country: United States
Website: https://www.marinrestorationgroup.com/

Spinal Muscular Atrophy Pipeline 2026: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Genentech, Chugai Pharma, Cytokinetics, Ionis Pharma, Genzyme Corp

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Spinal Muscular Atrophy pipeline constitutes 18+ key companies continuously working towards developing 20+ Spinal Muscular Atrophy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

 

The Spinal Muscular Atrophy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

“Spinal Muscular Atrophy Pipeline Insight, 2026" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Spinal Muscular Atrophy Market.

 

Get a Free Sample PDF Report to know more about Spinal Muscular Atrophy Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/spinal-muscular-atrophy-sma-pipeline-insight

 

Some of the key takeaways from the Spinal Muscular Atrophy Pipeline Report:

• Companies across the globe are diligently working toward developing novel Spinal Muscular Atrophy treatment therapies with a considerable amount of success over the years.

• Spinal Muscular Atrophy companies working in the treatment market are Skyline Therapeutics, Exegenesis Bio, Biogen, GeneCradle Inc., Hangzhou Jiayin Biotech Ltd, Scholar Rock, Inc., Biohaven Pharmaceuticals, Inc, and others, are developing therapies for the Spinal Muscular Atrophy treatment

• Emerging Spinal Muscular Atrophy therapies in the different phases of clinical trials are- SKG 0201, Spinal muscular atrophy gene therapy, BIIB115, GC101, EXG001-307, Apitegromab, Talditercept alfa, and others are expected to have a significant impact on the Spinal Muscular Atrophy market in the coming years.

• In February 2026, Gemma Biotherapeutics (GEMMABio), a clinical-stage global developer of genetic therapies, announced that the first patient has been dosed in the Phase 1/2 CHARISMA trial evaluating GB221, an investigational next-generation gene therapy for SMA1. The CHARISMA study (NCT07070999) represents the first clinical assessment of a next-generation gene therapy for SMA1 administered directly into the cerebrospinal fluid (CSF) via intracisterna magna (ICM) injection. Built on a proprietary central nervous system (CNS) platform licensed from the University of Pennsylvania, GB221 is designed to deliver a functional, codon-optimized SMN1 gene using a modified transgene expression cassette, aimed at minimizing risks such as overexpression-related toxicity and sensory neurotoxicity.

• In December 2025, The Emirates Drug Establishment (EDE) has approved Itvisma™ (onasemnogene abeparvovec), a gene therapy using an adeno-associated viral vector to treat spinal muscular atrophy (SMA) in eligible adults and children aged two years and older. With this approval, the UAE becomes the second country worldwide to authorize this therapy, highlighting its commitment to accelerating patient access to advanced medical innovations. Itvisma addresses the genetic root of SMA by replacing the defective gene, improving motor function and reducing dependence on long-term treatments.

• In June 2025, Roche announced that the European Commission (EC) has approved a label extension for Evrysdi (risdiplam), introducing a room-temperature stable 5mg tablet for spinal muscular atrophy (SMA). The 6.5mm tablet can be swallowed whole or dispersed in water, taken with or without food, and stored without refrigeration. Designed for home administration, Evrysdi remains a convenient, non-invasive, disease-modifying therapy for individuals with SMA.

• In June 2025, Biogen Inc. (Nasdaq: BIIB) announced topline data from its Phase 1 study of salanersen (BIIB115/ION306), an investigational antisense oligonucleotide (ASO) for spinal muscular atrophy (SMA). Developed to provide greater potency than SPINRAZA (nusinersen) while working through the same mechanism, salanersen is intended to offer strong efficacy with a single annual dose. Interim results, which also included SMA patients with prior gene therapy, support advancement into registrational studies. Both 40 mg and 80 mg once-yearly doses were well-tolerated and showed significant neuroprotection, evidenced by neurofilament decline and promising functional gains, including attainment of new WHO milestones.

• In March 2025, Novartis’ investigational therapy OAV101 IT, an intrathecal version of the approved gene therapy onasemnogene abeparvovec (Zolgensma), has demonstrated encouraging outcomes in improving patient scores on the Hammersmith Functional Motor Scale Expanded (HFMSE). The results, from the Phase 3 STEER trial (NCT05089656), were recently shared at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference.

• In March 2025, Novartis announced favorable efficacy and safety results from its Phase III clinical program evaluating OAV101 IT (onasemnogene abeparvovec), an investigational intrathecal therapy for spinal muscular atrophy (SMA) in patients aged two to under 18 years. In the pivotal Phase III STEER trial, treatment with OAV101 IT led to a 2.39-point increase on the Hammersmith Functional Motor Scale Expanded (HFMSE), compared to a 0.51-point gain in the sham control group highlighting a significant improvement in motor function specific to SMA.

• In March 2025, Scholar Rock’s spinal muscular atrophy (SMA) treatment demonstrated improvements in muscle function among children under 12 in a key clinical study, yet the results failed to excite investors. The Phase III SAPPHIRE trial (NCT05156320) assessed the safety and effectiveness of apitegromab, a monoclonal antibody designed to enhance muscle growth by targeting and inhibiting the inactive forms of myostatin specifically within skeletal muscle.

• In February 2025, A pilot clinical trial suggested that spinal cord stimulation (SCS) may help restore function in patients with spinal muscular atrophy (SMA) by gradually activating dormant motor neurons and enhancing leg muscle strength. Conducted by the University of Pittsburgh School of Medicine (NCT05430113), the study evaluated Medtronic’s Vectris SureScan device in three SMA patients. All participants demonstrated improved mobility, each increasing their distance in the six-minute walk test (6MWT)—a key indicator of muscle endurance—by at least 20 meters after three months of treatment.

• In January 2025, Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on developing novel therapies for spinal muscular atrophy (SMA), cardiometabolic conditions, and other serious diseases involving protein growth factors, has announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for apitegromab. This muscle-directed therapy is intended to deliver significant motor function improvement in individuals with SMA who are already receiving SMN-targeted treatments. The company also plans to submit a Marketing Authorisation Application to the European Medicines Agency in the first quarter of 2025.

• In January 2025, Analytics firm GlobalData has expressed a positive outlook on the future of Novartis’ gene therapy for spinal muscular atrophy (SMA), onasemnogene abeparvovec (OAV101 IT). The therapy may soon be accessible to a wider patient group, thanks to encouraging results from Novartis’ Phase III STEER trial (NCT05089656), in which the intrathecal version of the treatment successfully met its primary endpoint.

• In November 2024, Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company dedicated to developing and commercializing transformative therapies for various rare and common diseases, announced updates on the development programs for taldefgrobep alfa in Spinal Muscular Atrophy (SMA) and obesity.

• In November 2024, Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company dedicated to developing innovative therapies for spinal muscular atrophy (SMA), cardiometabolic conditions, and other severe diseases driven by protein growth factors, has announced positive and statistically significant topline results from the pivotal Phase 3 SAPPHIRE trial. These findings highlight the potential of apitegromab to transform the standard of care for SMA patients.

• In April 2024, Exegenesis Bio, a fast-expanding global leader in genetic medicine, has shared clinical efficacy and safety findings from its Phase 1/2 trial (EXG001-307) for Spinal Muscular Atrophy (SMA) Type I. The data was presented on May 8, 2024, during the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting in Baltimore, Maryland (poster #627).

 

Spinal Muscular Atrophy Overview

Spinal Muscular Atrophy (SMA) is a rare genetic disorder that affects the motor neurons in the spinal cord, leading to progressive muscle weakness and atrophy. It is caused by mutations in the SMN1 gene, which is responsible for producing a protein essential for motor neuron survival. Without enough of this protein, the nerve cells controlling muscles deteriorate, resulting in difficulty with movement, breathing, and swallowing. SMA ranges in severity, with Type 1 being the most severe and appearing in infancy. Early diagnosis and treatment, including gene therapies and SMN-enhancing drugs, can significantly improve quality of life and outcomes.

 

Stay ahead of emerging therapies and key developments in Spinal Muscular Atrophy with comprehensive pipeline insights, trends, and market analysis, Spinal Muscular Atrophy Clinical Trials Analysis

 

Emerging Spinal Muscular Atrophy Drugs Under Different Phases of Clinical Development Include:

• SKG 0201: Skyline Therapeutics

• Spinal muscular atrophy gene therapy: Exegenesis Bio

• BIIB115: Biogen

• GC101: GeneCradle Inc.

• EXG001-307: Hangzhou Jiayin Biotech Ltd

• Apitegromab: Scholar Rock, Inc.

• Talditercept alfa: Biohaven Pharmaceuticals, Inc

 

Spinal Muscular Atrophy Route of Administration

Spinal Muscular Atrophy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Oral

• Parenteral

• Intravenous

• Subcutaneous

• Topical

 

Spinal Muscular Atrophy Molecule Type

Spinal Muscular Atrophy Products have been categorized under various Molecule types, such as

• Monoclonal Antibody

• Peptides

• Polymer

• Small molecule

• Gene therapy

 

Spinal Muscular Atrophy Pipeline Therapeutics Assessment

• Spinal Muscular Atrophy Assessment by Product Type

• Spinal Muscular Atrophy By Stage and Product Type

• Spinal Muscular Atrophy Assessment by Route of Administration

• Spinal Muscular Atrophy By Stage and Route of Administration

• Spinal Muscular Atrophy Assessment by Molecule Type

• Spinal Muscular Atrophy by Stage and Molecule Type

 

DelveInsight's Spinal Muscular Atrophy Report covers around 20+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

 

Further Spinal Muscular Atrophy product details are provided in the report. Download the Spinal Muscular Atrophy pipeline report to learn more about the emerging Spinal Muscular Atrophy therapies

 

Some of the key companies in the Spinal Muscular Atrophy Therapeutics Market include:

Key companies developing therapies for Spinal Muscular Atrophy are - Genentech Inc, Chugai Pharmaceutical, Cytokinetics Inc., Ionis Pharmaceuticals Inc., Genzyme Corporation, Novartis International AG, Astellas Pharma Inc., Takeda Pharmaceutical Company Limited, PerkinElmer Inc., Pfizer Inc., UW Health, Novo Nordisk A/S, Cure SMA, Boehringer Ingelheim Gmbh, Biogen Inc, F. Hoffmann-La Roche AG, Catalyst Pharmaceutical, Salarius Pharmaceuticals Inc, Regeneron Pharmaceuticals Inc, Isis Pharmaceuticals Inc., PTC Therapeutics, Natera Inc, AstraZeneca PLC, and others.

 

Spinal Muscular Atrophy Pipeline Analysis:

The Spinal Muscular Atrophy pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Spinal Muscular Atrophy with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Spinal Muscular Atrophy Treatment.

• Spinal Muscular Atrophy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Spinal Muscular Atrophy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Spinal Muscular Atrophy market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Spinal Muscular Atrophy drugs and therapies

 

Spinal Muscular Atrophy Pipeline Market Drivers

• Increase in prevalence of Spinal Muscular Atrophy, increasing number of clinical trials and government funding for R&D are some of the important factors that are fueling the Spinal Muscular Atrophy Market.

 

Spinal Muscular Atrophy Pipeline Market Barriers

• However, lack of public knowledge of this rare medical condition, cost associated with the treatment and other factors are creating obstacles in the Spinal Muscular Atrophy Market growth.

 

Scope of Spinal Muscular Atrophy Pipeline Drug Insight

• Coverage: Global

• Key Spinal Muscular Atrophy Companies: Skyline Therapeutics, Exegenesis Bio, Biogen, GeneCradle Inc., Hangzhou Jiayin Biotech Ltd, Scholar Rock, Inc., Biohaven Pharmaceuticals, Inc, and others

• Key Spinal Muscular Atrophy Therapies: SKG 0201, Spinal muscular atrophy gene therapy, BIIB115, GC101, EXG001-307, Apitegromab, Talditercept alfa, and others

• Spinal Muscular Atrophy Therapeutic Assessment: Spinal Muscular Atrophy current marketed and Spinal Muscular Atrophy emerging therapies

• Spinal Muscular Atrophy Market Dynamics: Spinal Muscular Atrophy market drivers and Spinal Muscular Atrophy market barriers

 

Request for Sample PDF Report for Spinal Muscular Atrophy Pipeline Assessment and clinical trials

 

Table of Contents

1. Spinal Muscular Atrophy Report Introduction

2. Spinal Muscular Atrophy Executive Summary

3. Spinal Muscular Atrophy Overview

4. Spinal Muscular Atrophy- Analytical Perspective In-depth Commercial Assessment

5. Spinal Muscular Atrophy Pipeline Therapeutics

6. Spinal Muscular Atrophy Late Stage Products (Phase II/III)

7. Spinal Muscular Atrophy Mid Stage Products (Phase II)

8. Spinal Muscular Atrophy Early Stage Products (Phase I)

9. Spinal Muscular Atrophy Preclinical Stage Products

10. Spinal Muscular Atrophy Therapeutics Assessment

11. Spinal Muscular Atrophy Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Spinal Muscular Atrophy Key Companies

14. Spinal Muscular Atrophy Key Products

15. Spinal Muscular Atrophy Unmet Needs

16 . Spinal Muscular Atrophy Market Drivers and Barriers

17. Spinal Muscular Atrophy Future Perspectives and Conclusion

18. Spinal Muscular Atrophy Analyst Views

19. Appendix

20. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/